Investors should closely monitor for any announcements of new financing, a partnership deal for lacutamab, or a dilutive capital raise. The stock price is highly vulnerable to negative news on funding. The planned H2 2026 catalysts (PACIFIC-9 and TELLOMAK-3 initiation) are contingent on securing financing.
Price Chart
Executive Summary
Innate Pharma's 20-F filing confirms a cash runway into Q3 2026 but highlights a critical funding gap, necessitating non-dilutive financing or a partnership for its lead asset lacutamab. While clinical progress on lacutamab and IPH4502 is positive, the company's ability to continue as a going concern is in doubt without immediate financing, creating significant risk for investors.
Key Facts
- Cash, cash equivalents, and short-term investments were $34.3 million as of December 31, 2025.
- The company's cash runway is expected to last only until the end of Q3 2026.
- The filing explicitly states that cash is insufficient to fund operations for the next 12 months, raising 'material uncertainty' about its ability to continue as a going concern.
- The planned Phase 3 trial for lacutamab is 'subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures.'
- The company incurred a net loss of $49.2 million in 2025, and its equity is negative at $26.4 million.
Financial Impact
The company requires immediate financing to avoid a liquidity crisis. Without it, operations could be severely curtailed or halted.
Risk Factors
- The company may not secure the necessary financing, leading to a restructuring or significant operational downsizing.
- If financing is secured, it could be highly dilutive to existing shareholders.
- The failure to initiate the lacutamab Phase 3 trial would be a major setback for the company's lead asset.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001598599-26-000005 |
| Exhibit: exhibit23fy2025.htm | 0001598599-26-000005 |
| Exhibit: exh_11fy2025.htm | 0001598599-26-000005 |
| Exhibit: exhibit971.htm | 0001598599-26-000005 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 19, 2026 22w ago | 6-K | $2.25 $1.65 | ▼ −26.67% | ▼ −32.96% | $1.51 (−32.93%) |
May 13, 2026 23w ago | 6-K | $1.50 $1.65 | ▼ −10.00% | ▼ −5.56% | $1.51 (−0.60%) |
May 6, 2026 24w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +7.94% | $1.51 (+0.60%) |
Apr 23, 2026 26w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +4.98% | $1.51 (+0.60%) |
Apr 17, 2026 27w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +3.86% | $1.51 (+0.60%) |
Apr 13, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +11.25% | $1.51 (+9.91%) |
Apr 13, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +11.25% | $1.51 (+9.91%) |
Apr 8, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +9.72% | $1.51 (+9.91%) |
Apr 3, 2026 29w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +6.71% | $1.51 (+9.91%) |
Apr 1, 2026 29w ago | 20-F | $1.37 $1.65 | ▼ −20.17% | ▼ −6.80% | $1.51 (−9.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers